Plandai's Phytofare(TM) Catechin Complex to Fight Child Obesity

Marketwired

BALTIMORE, MD--(Marketwired - Aug 7, 2013) - Goldman Small Cap Research, a stock market research firm focused on the small cap and microcap sectors, notes in a just published article that Plandai Biotechnology, Inc. (OTCQB: PLPL), which is slated engage in a weight loss study to test the efficacy of its flagship product, is well-positioned to assist in the fight against child obesity. 

It is no secret that the U.S. is in a war with childhood obesity. After all, the statistics are alarming. According to the Centers for Disease Control and Prevention (CDC), childhood obesity has more than doubled in children and tripled in adolescents in the past 30 years. The CDC website also reports that recent statistics note that more than one third of children and adolescents were overweight or obese.

With a 90 subject, three month weight loss study slated to commence later this year, Plandai Biotechnology, Inc. is well-positioned to assist in reducing this disturbing trend. Previous green tea extract weight loss studies, exclusively using children as subjects have not had a great deal of success due to limited bioavailability (nutrient absorption rate into the bloodstream.) However, in its pending trials, the Company's Phytofare™ Catechin Complex should be able to demonstrate significant health benefits, including weight loss, owing to its industry-leading absorption levels. Success in this trial would likely turn the product into the go-to prevention ingredient and offering in weight loss for adults and children.

Many parents would gladly migrate their children's consumption habits away from sugary soft drinks to healthier alternatives that can aid in weight loss and general wellness. Of course, the benefits to the immune system and overall wellness derived from green tea extracts are well documented. These characteristics have sharply driven the consumption of green tea and the catechins associated with its disease prevention and health benefit properties. Still, the Holy Grail for parents would be a delivery system that offers are seeking greater bioavailability along with caffeine-free alternatives, which the Company would likely be able to accommodate, pending the outcome of the future trials. 

As a potential provider of the offering of choice in obesity prevention for adults and children, Plandai's offerings appear poised to be rewarded with an extremely high profile resulting in significant sales in the U.S. and abroad.

Goldman Small Cap Research articles and reports on Plandai as well as associated disclaimers can be accessed or downloaded in their entirety by visiting www.goldmanresearch.com.

About Goldman Small Cap Research: Led by former Piper Jaffray analyst and mutual fund manager Rob Goldman, Goldman Small Cap Research produces sponsored and non-sponsored small cap and micro cap stock research reports, articles, daily stock market blogs, and popular investment newsletters. For more information, visit www.goldmanresearch.com.

A Goldman Small Cap Research report is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed. Please read the report's full disclosures and analyst background on our website before investing. Neither Goldman Small Cap Research nor its parent is a registered investment adviser or broker-dealer with FINRA or any other agency. To download our research, view our disclosures, or for more information, visit www.goldmanresearch.com.

About Plandai Biotechnology, Inc. (OTCQB: PLPL): Plandai Biotechnology, Inc. and its subsidiaries develop highly bioavailable, phytonutrient rich extracts, which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology controls every aspect of the process, from growing the raw materials on its farms in South Africa, to producing the patented pending Phytofare™ extracts in-house allowing the Company to guarantee the continuity of supply as well as quality control throughout. Targeted industries for the Company's products include food and beverage, cosmeceutical, wellness, nutraceutical, anti-aging, and pharmaceutical. For more information, please visit http://www.plandaibiotech.com.

Contact:
Goldman Small Cap Research
Rob Goldman
Analyst
410-609-7100
rob@goldmanresearch.com

Rates

View Comments (0)